ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes The ...
ADCE-D01 is a first-in-class antibody-drug conjugate targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes Fast Track ...
ADCE-D01 targets the uPARAP protein in sarcomas, delivering medication directly to cancer cells, showing promise in early studies. The ADCElerate1 trial evaluates ADCE-D01's safety, tolerability, ...
PARIS--(BUSINESS WIRE)--Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, is leading an oversubscribed $75 million (€ 65 million 2) Series C financing ...
ADCE-T02 - a potential first and best-in-class topoisomerase-1 (Topo-1) inhibitor-based Antibody-Drug Conjugate (ADC) against Tissue Factor - demonstrates strong and broad preclinical efficacy and ...
Adcendo, a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for cancer treatment, has raised $75m in a Series C funding round. The financing will support Adcendo’s ...
Adcendo, a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, announced that the US Food & Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results